Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Lithium Americas Corp (LAC) Price & Performance

Cassava Sciences IncTrade
Lithium Americas CorpTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Lithium Americas Corp — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Lithium Americas Corp trades at $3.26 (market cap $1.18B). The key difference: Lithium Americas Corp is far larger — about 24.7× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.

FLNALAC
Market Cap
$47.75M$1.18B
Sector
HealthBasic Materials
52-Week High
$4.64$10.05
52-Week Low
$0.87$2.71
Enterprise Value
-$34.93M$1.29B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

Lithium Americas Corp

Lithium Americas (LAC) trades at $3.25 with mixed technical signals showing a bullish overall trend but neutral oscillators. The company reported negative profitability metrics with ROE at -11.35% and net income of -$122.09M for 2025, though it secured $175M financing for Thacker Pass construction. Recent earnings show volatility with two beats and one miss in the last four quarters.

LAC faces significant execution risks with substantial capital expenditures needed, but analyst sentiment remains positive with 7 buy ratings and no sell recommendations. The stock's valuation at 0.88 P/B suggests potential upside if lithium demand recovers, though negative cash flow from operations and high investing outflows present near-term challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC